After such promising results, a phase II clinical trial has been designed to evaluate the CDK 4/6-inhibitor ribociclib in solid tumours, including MM carrying relevant CDK4/6, cyclin D1/3 or p16 aberrations (NCT02187783). This evidence concerns the gene CCND1 and Miyoshi myopathy.